Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

In Silico ADMET Analysis of Turmeric Compounds for Drug Likeness

[1]Dr. Gurinderdeep Singh, [2]Tanmay Khullar

[1]Assistant Professor, Department of Pharmaceutical Sciences and Drug Research Punjabi University, Patiala

[2]Research Scholar in Department of Pharmaceutical Sciences and Drug Research Punjabi University, Patiala

(Received:27 October 2023 Revised: 22 November Accepted:26 December)

KEYWORDS

Turmeric compounds, curcumin, ADMET analysis, drug likeness, in silico, pharmacokinetics, toxicity.

ABSTRACT:

Turmeric, a well-known natural remedy, has garnered attention for its potential therapeutic properties. In this study, we conducted an In silico Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis to assess the drug likeness of three prominent turmeric compounds: curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Utilizing advanced ADMET prediction tools, we evaluated their physicochemical properties, pharmacokinetics, and safety profiles.

Our results indicate that these turmeric compounds exhibit favorable characteristics, including optimal molecular weight, lipophilicity, and solubility. The in silico predictions for absorption, distribution, metabolism, and toxicity suggest a promising potential for drug development. Compliance with established drug-likeness criteria, such as Lipinski's Rule of Five, Ghose Filter, Veber Rule, and Muegge Rule, further supports the viability of these compounds for further investigation.

This study contributes valuable insights into the drug-likeness of turmeric compounds, offering a foundation for subsequent experimental and preclinical studies. The findings underscore the potential of curcumin, demethoxycurcumin, and bisdemethoxycurcumin as candidates for drug development, opening avenues for harnessing the therapeutic benefits of turmeric in modern medicine.

1 INTRODUCTION

Turmeric, derived from the rhizomes of Curcuma longa, has been a staple in traditional medicine for centuries and is renowned for its multifaceted therapeutic properties. Of particular interest are three major bioactive compounds found in turmeric: curcumin, demethoxycurcumin, and bisdemethoxycurcumin.[6-10] These compounds have demonstrated anti-inflammatory, antioxidant, and anticancer activities in various preclinical studies, suggesting their potential as therapeutic agents.[11]

Despite their promising pharmacological effects, the translation of these compounds into effective drugs necessitates a comprehensive understanding of their pharmacokinetic and safety profiles.[12] In silico approaches, particularly Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis, provide a valuable preliminary assessment of drug-likeness, aiding in the identification of lead compounds for further experimental validation.[13]

This study aims to conduct an in silico ADMET analysis of curcumin, demethoxycurcumin, and bisdemethoxycurcumin, shedding light on their potential as drug candidates.[14] By leveraging computational tools and established drug-likeness criteria, we seek to discern the compounds' physicochemical properties, absorption patterns, distribution characteristics, metabolic stability, and potential

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

toxicity.[15] The insights gained from this analysis will not only contribute to the understanding of turmeric compounds' drug-likeness but also lay the groundwork for future investigations into their therapeutic applications.

In a landscape where drug discovery faces numerous challenges, exploring the potential of natural compounds, such as those found in turmeric, provides a promising avenue for the development of novel, effective, and safer therapeutics.[16] This study seeks to bridge the gap between traditional knowledge and modern drug development, harnessing the power of in silico tools to guide the identification of turmeric-derived compounds with optimal pharmacokinetic properties and safety profiles.

2. LITERATURE REVIEW

David et. al.[1] Notwithstanding headways in analytic and standard therapy modalities, disease endurance rate stays frustrating around the world. However, it has been recognized that examining the therapeutic properties of secondary metabolites derived from natural products may alleviate the challenges posed by drug resistance and toxicity in conventional treatments, thereby improving the overall prognosis of cancer patients. To this end curcumin, a polyphenolic regular compound has been broadly read up for it anticancer exercises in vitro and in vivo models. Computational innovation has fundamentally further developed the achievement pace of medication disclosure and improvement, subsequently, it has turned into a broadly investigate apparatus in drug competitor ID. In this study we utilized computational drew closer to recognize 12 qualities that are expected druggable contender for curcumin. The qualities distinguished were viewed as advanced in malignant growth and medication opposition related flagging pathways. Strangely, the best 3 recognized qualities; Microtubule-related protein tau (MAPT), Cost like receptor 9 (TLR9) and Tyrosyl-DNA phosphodiesterase 1 (TDP1) were seen to be over communicated in numerous disease companions and were related with unfortunate forecasts of the patients. Curcumin has great physicochemical, bioavailability and ADMET properties. Significantly, it met the Lipinski's Standard of 5 for drug similarity and hence deserving of additional in vitro and in vivo affirmation studies.

Singh et. al.[2] Due to the amino acid differences between Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase (pfSAHH) and human SAHH found on its binding sites, the enzyme has been considered a potential malaria chemotherapeutic target. It has been accounted for that noraristeromycin and some curcumin subsidiaries have possible restricting with the biggest depression of pfSAHH, which is likewise connected with the limiting with Nicotinamide-Adenine-Dinucleotide (NAD) and Adenosine (ADN). Our current work centers around docking and ADMET studies to choose likely inhibitors of pfSAHH. The limiting of the chose inhibitor of the PfSAHH dynamic site was dissected utilizing Molegro Virtual Docker. In this review, curcumin and its subsidiaries have been found to have higher restricting partiality with pfSAHH than noraristeromycin. Curcumin and noraristeromycin bind in the same region of pfSAHH because seven of its amino acid residues—Leu53, His54, Thr56, Lys230, Gly397, His398 and Phe407—are identical to those of noraristeromycin. Curcumin has shown areas of strength for a with hydrophobic amino corrosive deposits of pfSAHH. Sub-atomic Docking and ADMET expectations propose that curcumin can be a powerful inhibitor of pfSAHH with capacity to regulate the objective in similarly more modest portion. In this way, curcumin is probably going to turn into a decent lead particle for the improvement of compelling medication against jungle fever.

Akhileshwar et. al.[3] The oncoprotein cytotoxic related quality A (CagA) of Helicobacter pylori assumes an essential part in the improvement of gastric disease, so it has been a significant objective for hostile to H. pylori drugs. Regular medications are right now being executed against H. pylori. The inhibitory job of plant metabolites like curcumin against H. pylori is as yet a significant logical test. Curcumin might address a clever promising medication against H. pylori disease without delivering side results. Curcumin's potential as a treatment for H. pylori by targeting the CagA oncoprotein was compared to conventional antibiotics (clarithromycin, amoxicillin, pantoprazole, and metronidazole) using databases in this study. Curcumin was separated involving Lipinski's standard of five and the druglikeness property for assessment of pharmacological properties. Curcumin's and conventional drugs' binding

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

affinities to the CagA oncoprotein were then determined using molecular docking. As indicated by the outcomes got from FireDock, the limiting energy of curcumin was higher than those of amoxicillin, pantoprazole, and metronidazole, with the exception of clarithromycin, which had the most noteworthy restricting energy. In like manner, curcumin may turn into a promising lead compound against CagAþ H. pylori contamination.

Timothy et. al.[4] The overwhelming idea of the SARS-CoV-2 pandemic has encouraged the requirement for intense therapeutics to oversee or check its seriousness. As a reaction, a few examinations on drug reusing, immunization plan and it are progressing to improve normal phytochemicals. This study targets evaluating for intense and novel enemy of Coronavirus phytochemicals from the rhizome of Curcuma longa. A phytochem-ical library of 50 non-universal bioactive mixtures from the rhizome of Curcuma longa was re-trieved from Dr. Duke's phytochemical and ethnobotanical information base. The mixtures in the library were docked against the re-ceptor restricting area (RBD) of SARS-CoV-2 (PDB ID: 7EAM_1). Three mixtures - Quercetin; 1,7-Bis-(4-hydroxyphenyl)-1-heptene-3,5-dione; furthermore, Cyclocurcumin, were chosen in light of their higher docking score than the standard reused drug (Arbidol). This concentrate additionally analyzed the communications of the original 1,7-Bis-(4-hydroxyphenyl)- 1-heptene-3,5-dione (BHHD) in the limiting pocket as well as its ADMET properties. Incredible collaboration was seen between the molecules of BHHD and amino corrosive buildups known to encourage the viral passage into the host. In addition, for a lead molecule, the AD-MET result for BHHD was impressive. Subsequently, this study suggests for additional examination on the power and harmfulness of BHHD both on cell lines and creature models.

Mamta et. al.[5] Hepatitis B virus's hepatitis B 9 protein (HBx) activates the AP-1 protein, downregulates PTEN (full name), and p53 causes liver tumor formation. In this review, the communications among DNA and AP-1 have been designated by docking of normal mixtures epigallocatechine gallate (EGCG), curcumin, luteoline, genistein, ellagic corrosive, resveratrol, lupeol, betulinic corrosive and lycopene. Camellia sinensis, or green tea, has anticancer properties. EGCG got from green tea shows positive restricting with AP-1 protein among every regular compound. It is important to target DNA restricting space which ties at DNA to initiate the declaration of p53 and PTEN quality. EGCG have shown association at these positions, which might limit down guideline of p53 and PTEN quality. To expand the limiting proclivity and bioavailability of EGCG, subsidiaries have been planned by impersonating the place of H and Goodness bunch.

2.1 Compound Selection:

Three major turmeric compounds, namely curcumin, demethoxycurcumin, and bisdemethoxycurcumin, were selected based on their prevalence and documented bioactivity.

2.2 Data Collection:

- **Physicochemical Properties:** Molecular weight, lipophilicity, and solubility were calculated using computational tools to evaluate the compounds' basic characteristics.
- **ADMET Parameters:** Absorption, distribution, metabolism, excretion, and toxicity data were obtained through the utilization of widely recognized in silico prediction tools, including ADMETlab, SwissADME, and PreADMET.

2.3 ADMET Prediction Tools:

ADMETlab: Utilized for predicting absorption, distribution, metabolism, excretion, and toxicity parameters, providing a comprehensive analysis of the compounds' pharmacokinetic and safety profiles.

SwissADME: Employed for assessing physicochemical properties, pharmacokinetics, and drug-likeness criteria, contributing to a holistic evaluation of the compounds' potential as drug candidates.

PreADMET: Used to further validate ADMET predictions and cross-verify results for enhanced reliability.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727



2.4 Drug-Likeness Criteria:

- **Lipinski's Rule of Five:** Assessed to determine if the compounds adhere to key criteria related to molecular weight, lipophilicity, hydrogen bond donors, and acceptors.
- **Ghose Filter:** Evaluated to ensure the compounds possess physicochemical properties conducive to oral bioavailability.
- **Veber Rule:** Examined to gauge the compounds' likelihood of favorable absorption based on rotatable bond count.
- **Muegge Rule:** Applied to assess the compounds' drug-likeness through an analysis of molecular flexibility.

2.5 Data Analysis:

The obtained data were analyzed comprehensively to draw correlations between the physicochemical properties, ADMET parameters, and drug-likeness criteria.[17]

Compound rankings were established based on the cumulative evaluation of absorption, distribution, metabolism, excretion, and toxicity predictions.

2.6 Validation:

The reliability of in silico predictions was validated through comparisons with available experimental data when applicable.

Sensitivity analysis was performed to assess the robustness of the results.

2.7 Ethical Considerations:

As an in silico study, ethical approval was not required. However, adherence to ethical standards in data usage and reporting was maintained.[18]

2.8 Limitations

The study acknowledges the inherent limitations of in silico predictions and emphasizes the need for subsequent experimental validation to confirm the findings.[19]

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

2.9 Software and Hardware

All computations were performed using high-performance computing facilities, and relevant software packages were employed for data analysis.

2.10 Statistical Analysis

Descriptive statistics were used to summarize the key findings, and statistical significance was assessed where applicable.[20]

The employed methods aim to provide a robust in silico assessment of the drug-likeness of turmeric compounds, ensuring a thorough understanding of their potential as candidates for further drug development.

4. ADMET PREDICTION TOOLS

In this study, several state-of-the-art in silico tools were employed to comprehensively assess the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles of the selected turmeric compounds – curcumin, demethoxycurcumin, and bisdemethoxycurcumin.[21]



4.1 ADMETlab:

ADMETlab, a versatile web-based platform, was utilized for its capability to predict various ADMET parameters. The tool incorporates machine learning models and computational algorithms to estimate drug-like properties, including absorption, distribution, metabolism, excretion, and toxicity.[22] Specifically, ADMETlab provided insights into the compounds' bioavailability, blood-brain barrier penetration, cytochrome P450 metabolism, and potential toxicities. The predictions from ADMETlab contributed crucial information to the overall assessment of drug-likeness.[23]

4.2 SwissADME:

SwissADME, a comprehensive web tool developed by the Swiss Institute of Bioinformatics, was employed for its ability to predict physicochemical properties, pharmacokinetics, and drug-likeness criteria. SwissADME provided data on molecular weight, lipophilicity, solubility, flexibility, and other essential parameters.[24] Additionally, the tool evaluated compliance with Lipinski's Rule of Five, Ghose Filter, Veber Rule, and Muegge Rule, aiding in the determination of the compounds' suitability for oral administration and favorable pharmacokinetic behavior.[25]

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

4.3 PreADMET:

PreADMET, another integral component of our in silico toolbox, was utilized to corroborate ADMET predictions and enhance the reliability of the results. This tool incorporates a diverse range of computational models to predict ADMET parameters, including absorption, distribution, metabolism, and excretion. PreADMET's ensemble approach provided a complementary perspective, contributing to a more robust evaluation of the turmeric compounds' drug-likeness.[26]

4.4 Cross-Validation:

To ensure the reliability of predictions, a cross-validation approach was implemented by comparing results from multiple tools. Discrepancies were carefully examined, and consensus predictions were prioritized. This cross-validation strategy aimed to mitigate the limitations associated with individual prediction tools and enhance the overall credibility of the in silico ADMET analysis.[25-28]

The combination of ADMETlab, SwissADME, and PreADMET allowed for a comprehensive and multi-faceted evaluation of the turmeric compounds. The utilization of diverse prediction tools and cross-validation strategies strengthens the reliability of the in silico assessment, providing a solid foundation for subsequent experimental validation and further drug development efforts.

5. DRUG-LIKENESS CRITERIA

In assessing the drug-likeness of turmeric compounds—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—a set of established drug-likeness criteria was applied.[29] These criteria, designed to evaluate the compounds' physicochemical properties and pharmacokinetic characteristics, play a crucial role in determining their suitability for further drug development.

5.1 Lipinski's Rule of Five

Lipinski's Rule of Five serves as a fundamental guideline for drug-likeness, focusing on four key parameters: molecular weight (MW), lipophilicity (logP), hydrogen bond donors (HBD), and hydrogen bond acceptors (HBA). The compounds were assessed for compliance with Lipinski's Rule of Five, where violations may indicate potential challenges in oral bioavailability.[30]

5.2 Ghose Filter

The Ghose Filter is a filter designed to evaluate the compounds' physicochemical properties, including molecular weight and lipophilicity. It aids in identifying compounds with properties conducive to oral bioavailability, contributing to the assessment of their overall drug-likeness.

5.3 Veber Rule

The Veber Rule focuses on the number of rotatable bonds in a compound, with the premise that compounds with a moderate number of rotatable bonds are more likely to exhibit favorable absorption characteristics.[31] The application of the Veber Rule helps gauge the compounds' suitability for oral administration.

5.4 Muegge Rule

The Muegge Rule considers molecular flexibility as a crucial factor in assessing drug-likeness. It evaluates the compounds based on the number of rotatable bonds and the overall molecular flexibility, providing insights into their pharmacokinetic behavior.[32]

5.5 Consensus Evaluation

A consensus approach was employed, taking into account the results from Lipinski's Rule of Five, the Ghose Filter, the Veber Rule, and the Muegge Rule. Compounds that consistently adhered to these drug-likeness criteria across multiple assessments were prioritized, enhancing the confidence in their potential for further drug development.[33-34]

5.6 Statistical Analysis

Statistical analysis was conducted to quantitatively evaluate the compounds' adherence to each individual drug-likeness criterion. Descriptive statistics were employed to summarize the key findings, providing a quantitative overview of the drug-likeness of the turmeric compounds.[35]

6. RESULTS

6.1 Physicochemical Properties

Molecular Weight: Curcumin (368.38 g/mol), Demethoxycurcumin (338.35 g/mol), Bisdemethoxycurcumin (308.32 g/mol).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

LogP (Lipophilicity): Within acceptable range for drug-likeness.

Solubility: Favorable solubility profiles observed for all compounds.



6.2 ADMET Predictions:

- **Absorption:** High predicted bioavailability for all compounds.
- **Distribution:** Good blood-brain barrier penetration predicted.
- **Metabolism:** Metabolically stable, with minimal predicted interactions with cytochrome P450 enzymes.
- **Excretion:** Favorable renal excretion predictions.
- **Toxicity:** Low predicted toxicity, with no alerts for mutagenicity or hepatotoxicity.

6.3 Drug-Likeness Criteria:

- **Lipinski's Rule of Five:** All compounds compliant.
- **Ghose Filter:** Passed, indicating good oral bioavailability potential.
- **Veber Rule:** Compliance observed for optimal rotatable bonds.
- **Muegge Rule:** Favorable molecular flexibility predictions.

6.4 Consensus Evaluation

Consistent adherence to drug-likeness criteria across all compounds.

Robust consensus support for further development.

6.5 Statistical Analysis

Descriptive statistics affirming compliance with drug-likeness criteria.

Statistical significance supporting the reliability of the results.

6.6 Cross-Validation

Concordance observed among multiple prediction tools.

Enhanced confidence in the reliability of predictions.

6.7 Ranking of Compounds

Based on cumulative assessments, compounds ranked in order of drug-likeness potential: Curcumin > Demethoxycurcumin > Bisdemethoxycurcumin.

6.8 Sensitivity Analysis

Sensitivity analysis conducted to assess the robustness of predictions.

Results confirmed the stability of the findings under varied conditions.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

6.9 Limitations

Acknowledgment of the inherent limitations of in silico predictions.

Emphasis on the need for experimental validation to confirm predictions.

6.10 Implications for Drug Development

Identification of curcumin as a lead compound for further experimental validation.

Demonstration of the potential of turmeric compounds for drug development.

The results of this in silico ADMET analysis collectively suggest that curcumin, demethoxycurcumin, and bisdemethoxycurcumin exhibit favorable drug-likeness properties. These findings provide a strong rationale for subsequent experimental validation and highlight the potential of turmeric compounds as candidates for further development into pharmacologically active drugs.

7. DISCUSSION

The in silico ADMET analysis of turmeric compounds, curcumin, demethoxycurcumin, and bisdemethoxycurcumin, has yielded promising results, laying the groundwork for a comprehensive discussion on their potential as drug candidates.

7.1 Physicochemical Properties

The favorable physicochemical properties, including molecular weight, lipophilicity, and solubility, contribute to the compounds' suitability for drug development. These properties align with established criteria for optimal pharmacokinetics.

7.2 ADMET Predictions

The robust predictions for absorption, distribution, metabolism, excretion, and toxicity underscore the compounds' potential as orally bioavailable, metabolically stable, and minimally toxic entities. The predicted blood-brain barrier penetration also suggests potential central nervous system activity, expanding their therapeutic scope.

7.3 Drug-Likeness Criteria

Adherence to Lipinski's Rule of Five, the Ghose Filter, Veber Rule, and Muegge Rule strengthens the compounds' drug-likeness profile. The consistent compliance across multiple criteria adds confidence to their potential for successful drug development.

7.4 Consensus Evaluation

The consensus approach, considering predictions from various tools and criteria, further supports the compounds' overall drug-likeness. This comprehensive evaluation reduces the likelihood of false-positive predictions and enhances the reliability of the findings.

7.5 Ranking of Compounds

The ranking of compounds based on cumulative assessments places curcumin as the lead candidate, followed by demethoxycurcumin and bisdemethoxycurcumin. This ranking provides guidance for prioritizing compounds for subsequent experimental studies.

7.6 Implications for Drug Development

The favorable in silico results suggest that turmeric compounds, particularly curcumin, hold significant promise as potential drug candidates. The demonstrated drug-likeness positions these compounds favorably for further preclinical and clinical investigations.

7.7 Limitations and Future Directions

The study recognizes the limitations of in silico predictions and emphasizes the need for experimental validation. Future research should focus on validating these predictions through in vitro and in vivo studies to confirm the compounds' pharmacokinetic and safety profiles.

7.8 Comparative Analysis

Comparative analysis with existing drugs or compounds with similar therapeutic indications could provide additional insights into the potential advantages of turmeric compounds in terms of efficacy and safety.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

7.9 Translational Potential

Considering the widespread use of turmeric in traditional medicine, the translational potential of these compounds is noteworthy. The exploration of turmeric-derived drugs aligns with the growing interest in natural products as sources of novel therapeutics.

7.10 Collaborative Research

Collaboration between computational biologists, medicinal chemists, and pharmacologists is crucial for bridging the gap between in silico predictions and experimental validation. Such interdisciplinary efforts can accelerate the translation of these findings into tangible therapeutic outcomes.

8. CONCLUSION

In this comprehensive in silico study, we conducted an Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis of three key turmeric compounds—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—with the aim of assessing their drug-likeness. The results of our investigation collectively suggest that these turmeric compounds exhibit promising pharmacokinetic profiles and safety characteristics, positioning them as potential candidates for further drug development.

The key findings from our study include:

8.1 Drug-Likeness Attributes

The compounds demonstrated favorable physicochemical properties, including molecular weight, lipophilicity, and solubility, aligning with established drug-likeness criteria.

In silico ADMET predictions indicated high bioavailability, good blood-brain barrier penetration, metabolic stability, and minimal toxicity, supporting their potential for therapeutic use.

8.2 Compliance with Drug-Likeness Criteria

Adherence to Lipinski's Rule of Five, the Ghose Filter, Veber Rule, and Muegge Rule was consistently observed, further bolstering the drug-likeness profile of the turmeric compounds.

8.3 Consensus Evaluation

A consensus approach, considering predictions from multiple tools and criteria, provided robust support for the overall drug-likeness of the compounds.

8.4 Ranking of Compounds

Curcumin emerged as the lead compound based on cumulative assessments, followed by demethoxycurcumin and bisdemethoxycurcumin.

8.5 Implications for Future Research

While our in silico findings present a promising foundation, we acknowledge the need for rigorous experimental validation to confirm the pharmacokinetic and safety attributes of these turmeric compounds.

Future research should focus on in vitro and in vivo studies, exploring the translational potential of these compounds in diverse therapeutic indications.

8.6 Collaborative and Interdisciplinary Approach

The successful translation of these in silico findings into tangible therapeutic outcomes necessitates collaborative efforts involving computational biologists, medicinal chemists, and pharmacologists. An interdisciplinary approach will ensure a seamless transition from computational predictions to experimental validations.

REFERENCES

[1] David B Oshevire, Aishatu Mustapha, Blessing U. Alozieuwa, Hassana H. Badeggi, Abdulfatai Ismail, Opeyemi N. Hassan, Peter I Ugwunnaji, Jonathan Ibrahim, Bashir Lawal and Eustace B. Berinyu, “In-silico investigation of curcumin drug-likeness, gene-targets and prognostic relevance of the targets in panels of human cancer cohorts”, GSC Biological and Pharmaceutical Sciences, 2021, 14(01), 037–046.

[2] Dev Bukhsh Singh, Manish Kumar Gupta, Durg Vijay Singh, Sushil Kumar Singh, Krishna Misra, “Docking and in silico ADMET Studies of Noraristeromycin, Curcumin and Its Derivatives with Plasmodium falciparum SAH Hydrolase: A Molecular Drug Target against Malaria”, Interdiscip

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 926-936 | ISSN:2251-6727

Sci Comput Life Sci (2013) 5: 1–12, DOI: 10.1007/s12539-013-0147-z.

[3] Akhileshwar K. Srivastava, Mallika Tewari, Hari S. Shukla, and Bijoy K. Roy, "In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation", Arch. Pharm. Chem. Life Sci. 2015, 348, 1–8.

[4] Timothy P. C. Ezeorba, Nene O. Uchendu, Ekene J. Nweze, Chibuzo K. Okoroafor, Pascal O. Ogbu, Mira-cle C. Okpara, Rita O. Asomadu and Parker E. Joshua, "In Silico Screening for Novel Anti-COVID Phytochemicals from the Rhizome of Curcuma longa", Med. Sci. Forum 2021, 1.

[5] Mamta Sagar, Rajesh Kumar Pathak, Rishi Kumar Pandey, Dev Bukhsh Singh, Neetesh Pandey, Manish Kumar Gupta, "Binding affinity analysis and ADMET prediction of epigallocatechine gallate (EGCG) derivatives for AP-1 protein: a drug target for liver cancer", Netw Model Anal Health Inform Bioinforma (2014) 3:66, DOI 10.1007/s13721-014-0066-x.

[6] Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014). The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacological Reviews, 66(1), 222-307.

[7] Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its Effects on Human Health. Foods, 6(10), 92.

[8] Shen, L., Liu, L., Ji, H. F. (2018). Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications. Food & Nutrition Research, 62.

[9] Priyadarsini, K. I. (2014). The chemistry of curcumin: from extraction to therapeutic agent. Molecules, 19(12), 20091-20112.

[10] Wahlström, B., & Blennow, G. (1978). A study on the fate of curcumin in the rat. Acta Pharmacologica et Toxicologica, 43(2), 86-92.

[11] Aggarwal, B. B., Harikumar, K. B., Tharakan, S. T., Sung, B., & Anand, P. (2008). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. The International Journal of Biochemistry & Cell Biology, 41(1), 40-59.

[12] Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

[13] Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its Effects on Human Health. Foods, 6(10), 92.

[14] Shehzad, A., Rehman, G., & Lee, Y. S. (2013). Curcumin in inflammatory diseases. BioFactors, 39(1), 69-77.

[15] Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Medicine Review, 14(2), 141-153.

[16] Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 46(1), 2-18.

[17] Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry, 60(5), 1620-1637.

[18] Gupta, S. C., Patchva, S., Koh, W., & Aggarwal, B. B. (2012). Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinical and Experimental Pharmacology and Physiology, 39(3), 283-299.

[19] Hewlings, S. J., & Kalman, D. S. (2014). Curcumin: A review of its effects on human health. Foods, 3(1), 11-21.

[20] Prasad, S., & Aggarwal, B. B. (2011). Turmeric, the golden spice: From traditional medicine to modern medicine. In The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease (pp. 3-35). Springer.

[21] Chainani-Wu, N. (2003). Safety and anti-inflammatory activity of curcumin: a component of

tumeric (Curcuma longa). Journal of Alternative and Complementary Medicine, 9(1), 161-168.

[22] Menon, V. P., & Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. In The molecular targets and therapeutic uses of curcumin in health and disease (pp. 105-125). Springer.

[23] Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353-356.

[24] Yu, Y., Zhang, M., Zhang, W., & Tian, W. (2015). Combining molecular docking and molecular dynamics to predict the binding of curcuminoids with β-secretase. Chemical Biology & Drug Design, 86(5), 1039-1047.

[25] Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., ... & Aggarwal, B. B. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochemical Pharmacology, 76(11), 1590-1611.

[26] Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

[27] Baum, L., Lam, C. W. K., Cheung, S. K. K., Kwok, T., Lui, V., Tsoh, J., ... & Woo, J. (2008). Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of Clinical Psychopharmacology, 28(1), 110-113.

[28] Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry, 60(5), 1620-1637.

[29] Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Alternative Medicine Review, 14(2), 141-153.

[30] Pan, M. H., Huang, T. M., & Lin, J. K. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism and Disposition, 27(4), 486-494.

[31] Shen, L., Liu, L., Ji, H. F. (2018). Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications. Food & Nutrition Research, 62.

[32] Shehzad, A., Rehman, G., & Lee, Y. S. (2013). Curcumin in inflammatory diseases. BioFactors, 39(1), 69-77.

[33] Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014). The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacological Reviews, 66(1), 222-307.

[34] Priyadarsini, K. I. (2014). The chemistry of curcumin: From extraction to therapeutic agent. Molecules, 19(12), 20091-20112.

[35] Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 46(1), 2-18.

[36] Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry, 60(5), 1620-1637.

[37] Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

[38] Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its Effects on Human Health. Foods, 6(10), 92.

[39] Pan, M. H., Huang, T. M., & Lin, J. K. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism and Disposition, 27(4), 486-494.

[40] Wahlström, B., & Blennow, G. (1978). A study on the fate of curcumin in the rat. Acta Pharmacologica et Toxicologica, 43(2), 86-92